Gynov SAS announces investment from eureKARE SA
Summary
Also Read: A Game-Changing Strategic Plan: Şişecam and Ciner Group will invest 4 Billion USD in the US Soda Ash Industry Many female-specific conditions such as polycystic ovaries, endometriosis, chronic vaginitis, preterm delivery risk, infertility, etc. Gynov utilizes robust scientific and medical evidence to select relevant, high quality molecules and has found microbiota modulators to have an increasing role in human health. Gynov’s business strategy is largely based on exclusive distribution contracts, by territory, with pharmaceutical companies that will promote the products to healthcare professionals through a dedicated sales force. Gynov provides solutions that bring a high benefit-risk ratio to patients and will likely be recommended by healthcare professionals, owing to a well-documented scientific track record. This partnership will allow us to accelerate the transformation of our pipeline with an expected rate of 3 new products per year and to expand our activities in key markets such as Brazil, Mexico and the United States.” “Beyond its proven know-how in terms of concepts and manufacturing capacity, Gynov brings to eureKARE a disruptive position in the women’s health market, consistent with its investments in the fields of microbiome and synthetic biology,” commented Rodolphe Besserve, CEO of eureKARE.